{"product_id":"regeno-blend-bpc-157-tb-500-cartalax-30mg-biolongevity-labs","title":"Regeno Blend (BPC-157, TB-500, Cartalax)X30mg","description":"\u003cp\u003eDescription--\u003cbr\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eResearch Overview\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis triple-blend peptide brings together three distinct molecular pathways studied in connective tissue research and cellular repair models.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003eBPC-157 Research Profile\u003c\/strong\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eBPC-157 is a stable gastric pentadecapeptide derived from human gastric juice proteins. Laboratory studies demonstrate its activity across vascular endothelial growth factor pathways and nitric oxide-dependent mechanisms[1][2].\u003c\/p\u003e\n\u003cp\u003eThe peptide shows particular activity in musculoskeletal tissue models, where it modulates growth hormone receptor expression in fibroblast cultures. Research documents its influence on ERK1\/2 signaling cascades that regulate cell proliferation and migration[3][4].\u003c\/p\u003e\n\u003cp\u003eStudies on wound healing models reveal rapid gene expression changes and angiogenic activity in laboratory settings[1][5]. The peptide demonstrates cytoprotective properties across diverse cell types in vitro[6].\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eTB-500 Research Profile\u003c\/em\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTB-500 is a 43-amino acid polypeptide that functions as the primary G-actin sequestering molecule in eukaryotic cells. Its molecular activity extends to actin cytoskeleton regulation and spatial control of polymerization at sites of cell movement[7][8].\u003c\/p\u003e\n\u003cp\u003eLaboratory models show TB-500 activates HIF-1α pathways under hypoxic conditions. The peptide influences cell migration patterns through controlled actin availability at leading cell edges[9][10].\u003c\/p\u003e\n\u003cp\u003eResearch demonstrates angiogenic signaling in vascular cell cultures. Studies document progenitor cell differentiation and anti-apoptotic activity in multiple tissue models[11][12][13].\u003c\/p\u003e\n\u003cp\u003eThe peptide shows measurable effects in dermal fibroblast migration assays and collagen deposition models[14][15].\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eCartalax Research Profile\u003c\/em\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCartalax is a tripeptide (Ala-Glu-Asp) belonging to the Khavinson bioregulator family. These short peptides demonstrate direct DNA interaction and nuclear penetration in cell culture models[16].\u003c\/p\u003e\n\u003cp\u003eResearch documents epigenetic modulation mechanisms through DNA methylation status changes. The peptide influences gene expression patterns without altering underlying genetic sequences[17][18].\u003c\/p\u003e\n\u003cp\u003eLaboratory studies show tissue-specific activity based on amino acid composition. Cell culture research reveals histone protein interactions that modify chromatin accessibility[19][20].\u003c\/p\u003e\n\u003cp\u003eThe peptide demonstrates proliferation marker changes in aging cell models. Research documents senescence-associated gene modulation in fibroblast cultures[16].\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003eComplementary Research Applications\u003c\/strong\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003cp\u003eThe three peptides operate through distinct molecular pathways in laboratory settings. BPC-157 targets vascular and growth factor systems. TB-500 regulates cytoskeletal dynamics and cell motility. Cartalax modulates gene expression at the chromatin level.\u003c\/p\u003e\n\u003cp\u003eThis blend provides researchers with multiple mechanistic entry points for studying connective tissue biology, cellular repair processes, and fibroblast activity in controlled in vitro applications.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor laboratory research use only.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eReferences\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eS. Seiwerth \u003cem\u003eet al.\u003c\/em\u003e, “Stable Gastric Pentadecapeptide BPC 157 and Wound Healing,” Frontiers Media SA, Jun. 2021. doi: 10.3389\/fphar.2021.627533.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.3389\/fphar.2021.627533\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.3389\/fphar.2021.627533\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eF. Amic \u003cem\u003eet al.\u003c\/em\u003e, “Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine,” Baishideng Publishing Group Inc., Dec. 2018. doi: 10.3748\/wjg.v24.i47.5366.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.3748\/wjg.v24.i47.5366\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.3748\/wjg.v24.i47.5366\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eC.-H. Chang, W.-C. Tsai, Y.-H. Hsu, and J.-H. Pang, “Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts,” MDPI AG, Nov. 2014. doi: 10.3390\/molecules191119066.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.3390\/molecules191119066\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.3390\/molecules191119066\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eT. Huang \u003cem\u003eet al.\u003c\/em\u003e, “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro,” Informa UK Limited, Apr. 2015. doi: 10.2147\/dddt.s82030.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.2147\/dddt.s82030\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.2147\/dddt.s82030\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eP. Sikiric \u003cem\u003eet al.\u003c\/em\u003e, “Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection\/Adaptive Cytoprotection\/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the Future,” The Editorial Office of Gut and Liver, Mar. 2020. doi: 10.5009\/gnl18490.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.5009\/gnl18490\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.5009\/gnl18490\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eM. Józwiak, M. Bauer, W. Kamysz, and P. Kleczkowska, “Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review,” MDPI AG, Jan. 2025. doi: 10.3390\/ph18020185.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.3390\/ph18020185\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.3390\/ph18020185\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eY. Xiong \u003cem\u003eet al.\u003c\/em\u003e, “Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury,” Wiley, Oct. 2012. doi: 10.1111\/j.1749-6632.2012.06683.x.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06683.x\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1111\/j.1749-6632.2012.06683.x\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eI. Scheller \u003cem\u003eet al.\u003c\/em\u003e, “Thymosin β4 is essential for thrombus formation by controlling the G-actin\/F-actin equilibrium in platelets,” Ferrata Storti Foundation (Haematologica), Aug. 2021. doi: 10.3324\/haematol.2021.278537.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.3324\/haematol.2021.278537\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.3324\/haematol.2021.278537\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eS. Tang \u003cem\u003eet al.\u003c\/em\u003e, “TMSB4 Overexpression Enhances the Potency of Marrow Mesenchymal Stromal Cells for Myocardial Repair,” Frontiers Media SA, Jun. 2021. doi: 10.3389\/fcell.2021.670913.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.3389\/fcell.2021.670913\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.3389\/fcell.2021.670913\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eY. Fan, Y. Gong, P. K. Ghosh, L. M. Graham, and P. L. Fox, “Spatial Coordination of Actin Polymerization and ILK–Akt2 Activity during Endothelial Cell Migration,” Elsevier BV, May 2009. doi: 10.1016\/j.devcel.2009.03.009.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/j.devcel.2009.03.009\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1016\/j.devcel.2009.03.009\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eD. C. Morris, M. Chopp, L. Zhang, and Z. G. Zhang, “Thymosin β4: a candidate for treatment of stroke?,” Wiley, May 2010. doi: 10.1111\/j.1749-6632.2010.05469.x.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05469.x\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1111\/j.1749-6632.2010.05469.x\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eY. Wang \u003cem\u003eet al.\u003c\/em\u003e, “Thymosin β4 released from functionalized self-assembling peptide activates epicardium and enhances repair of infarcted myocardium,” Ivyspring International Publisher, 2021. doi: 10.7150\/thno.52309.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.7150\/thno.52309\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.7150\/thno.52309\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eH. Peng \u003cem\u003eet al.\u003c\/em\u003e, “Thymosin-β4prevents cardiac rupture and improves cardiac function in mice with myocardial infarction,” American Physiological Society, Sep. 2014. doi: 10.1152\/ajpheart.00129.2014.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1152\/ajpheart.00129.2014\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1152\/ajpheart.00129.2014\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eJ. Jing \u003cem\u003eet al.\u003c\/em\u003e, “Cloning, Expression and Effects of P. americana Thymosin on Wound Healing,” MDPI AG, Oct. 2019. doi: 10.3390\/ijms20194932.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.3390\/ijms20194932\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.3390\/ijms20194932\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eG. Sosne and E. A. Berger, “Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis,” Elsevier BV, May 2023. doi: 10.1016\/j.intimp.2023.109953. https:\/\/doi.org\/10.1016\/j.intimp.2023.109953\u003c\/li\u003e\n\u003cli\u003eV. K. Khavinson, I. G. Popovich, N. S. Linkova, E. S. Mironova, and A. R. Ilina, “Peptide Regulation of Gene Expression: A Systematic Review,” MDPI AG, Nov. 2021. doi: 10.3390\/molecules26227053.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.3390\/molecules26227053\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.3390\/molecules26227053\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eV. Kh. Khavinson, N. S. Lin’kova, and S. I. Tarnovskaya, “Short Peptides Regulate Gene Expression,” Springer Science and Business Media LLC, Dec. 2016. doi: 10.1007\/s10517-016-3596-7.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1007\/s10517-016-3596-7\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1007\/s10517-016-3596-7\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eL. I. Fedoreyeva, I. I. Kireev, V. Kh. Khavinson, and B. F. Vanyushin, “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA,” Pleiades Publishing Ltd, Nov. 2011. doi: 10.1134\/s0006297911110022.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1134\/s0006297911110022\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1134\/s0006297911110022\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eA. V. Arutjunyan, I. G. Popovich, L. S. Kozina, and G. A. Ryzhak, “Peptide Regulation of Ageing: From Experiment to Practice,” Bentham Science Publishers Ltd., Feb. 2025. doi: 10.2174\/0118746098346230250116065407.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.2174\/0118746098346230250116065407\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.2174\/0118746098346230250116065407\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli\u003eL. I. Fedoreyeva, T. A. Smirnova, G. Ya. Kolomijtseva, V. Kh. Khavinson, and B. F. Vanyushin, “Interaction of short peptides with FITC-labeled wheat histones and their complexes with deoxyribooligonucleotides,” Pleiades Publishing Ltd, Feb. 2013. doi: 10.1134\/s0006297913020053.\u003cspan\u003e \u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1134\/s0006297913020053\" rel=\"noopener\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1134\/s0006297913020053\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cbr\u003e\u003cbr\u003eLabel--\u003cstrong\u003eProduct Specifications\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003e\u003cstrong\u003eSpecification\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth\u003e\u003cstrong\u003eBPC-157\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth\u003e\u003cstrong\u003eTB-500 (Thymosin Beta-4)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth\u003e\u003cstrong\u003eCartalax (AED)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val\u003c\/td\u003e\n\u003ctd\u003eAc-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser\u003c\/td\u003e\n\u003ctd\u003eAla-Glu-Asp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMolecular Formula\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eC\u003csub\u003e62\u003c\/sub\u003eH\u003csub\u003e98\u003c\/sub\u003eN\u003csub\u003e16\u003c\/sub\u003eO\u003csub\u003e22\u003c\/sub\u003e\n\u003c\/td\u003e\n\u003ctd\u003eC\u003csub\u003e212\u003c\/sub\u003eH\u003csub\u003e350\u003c\/sub\u003eN\u003csub\u003e56\u003c\/sub\u003eO\u003csub\u003e78\u003c\/sub\u003eS\u003c\/td\u003e\n\u003ctd\u003eC\u003csub\u003e12\u003c\/sub\u003eH\u003csub\u003e19\u003c\/sub\u003eN\u003csub\u003e3\u003c\/sub\u003eO\u003csub\u003e8\u003c\/sub\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e1419.5 g\/mol\u003c\/td\u003e\n\u003ctd\u003e4963.4 g\/mol\u003c\/td\u003e\n\u003ctd\u003e333.29 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCAS Number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e137525-51-0\u003c\/td\u003e\n\u003ctd\u003e77591-33-4\u003c\/td\u003e\n\u003ctd\u003e205640-90-0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePubChem CID\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e9941957\u003c\/td\u003e\n\u003ctd\u003e16132341\u003c\/td\u003e\n\u003ctd\u003e87815447\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBepecin, Bpc 15, Body protection compound 15, Pentadecapeptide\u003c\/td\u003e\n\u003ctd\u003eThymosin Beta 4, Thymosin β4, TB500, Timbetasin\u003c\/td\u003e\n\u003ctd\u003eT-31, AED, Alanyl-glutamyl-aspartic acid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003eDosage--\u003cstrong\u003eThis PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY.\u003c\/strong\u003e\u003cspan\u003e This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only.  This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug.\u003c\/span\u003e\u003c\/p\u003e","brand":"Biolongevity Labs","offers":[{"title":"Default Title","offer_id":47947410374811,"sku":"BPC-TB5-CARTA-30MG","price":31191.0,"currency_code":"INR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3694\/4795\/files\/BPC-TB5-CARTA-30MG-regeno-blend-bpc-157-tb-500-cartalax-30mg-RET.jpg?v=1770933379","url":"https:\/\/fmihealth.com\/products\/regeno-blend-bpc-157-tb-500-cartalax-30mg-biolongevity-labs","provider":"FMI health","version":"1.0","type":"link"}